Breaking News

Hollande Says France Will Carry Out Air Attacks in Iraq
Tweet TWEET

Agilent Technologies SureSelect Target Enrichment Now Available for Ion Proton Next-Generation Sequencing Systems

  Agilent Technologies SureSelect Target Enrichment Now Available for Ion
  Proton Next-Generation Sequencing Systems

Business Wire

SANTA CLARA, Calif. -- October 22, 2013

Agilent Technologies Inc. (NYSE:A) today introduced a new SureSelect target
enrichment solution that allows Ion Proton users to realize the full power of
their next-generation sequencers with the industry’s leading human exome and
custom DNA target enrichment solutions. SureSelect target enrichment is now
available for all major sequencing platforms, enabling researchers to achieve
the highest-performance target enrichment results with a variety of
sequencers.

“The adoption of desktop sequencers has increased dramatically over the past
few years, enabling next-generation sequencing to expand further into clinical
research,” said Jacob Thaysen, Agilent’s vice president of the Genomic
Solutions Division. “We are happy to provide Ion Proton researchers access to
one of the industry’s leading target enrichment solutions.”

Already used extensively with high-throughput and desktop sequencers,
SureSelect solutions yield high sensitivity and specificity with a fast, easy
workflow, generating sequencer-ready samples in only 1.5 days. A number of
other distinctive features include highly uniform sequencing coverage, with
more than 99 percent SNP concordance rates. SureSelect’s flexibility also
enables researchers to easily create custom panels specific to their targets
of interest with SureDesign, Agilent’s user-friendly online design software.

SureSelect Human All Exon V5 is the most widely used human exome kit and is
now available for Ion Proton researchers using the SureSelect TE Reagent Kit
for Ion Proton. Agilent provides high-performance flexibility and a complete
solution for next-generation target enrichment sequencing, including target
enrichment reagents, automation, QC and analysis. For more information, click
here to visit Agilent’s SureSelect Human All Exon Kits website.

About Agilent in Genomics

Agilent Technologies Inc. is a global leader in target enrichment for
next-generation sequencing and genomic microarrays. The Agilent SureSelect and
HaloPlex target enrichment systems enable researchers to easily choose which
segments of a genome to sequence, avoiding the time and expense needed to
sequence the entire genome. HaloPlex offers a same-day sample-to-sequencer
workflow, and SureSelect can accurately capture whole exomes and whole
methylomes in a single reaction. These are just two products arising from
Agilent’s expertise in synthesizing custom complex mixtures of long
oligonucleotides gained in microarray manufacturing. Additional product lines
built on this core technology include microarrays for genome-wide measurement
of gene expression and for comparative genomics hybridization, as well as
SureFISH, a highly specific and sensitive product line for oligonucleotide
fluorescent in situ hybridization. In addition to oligonucleotide-based
products, Agilent offers a microfluidic bioanlyzer to measure sample quality,
and a full set of reagents, hardware, methods and bioinformatics software for
genomic experiments.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news
is available at www.agilent.com/go/news.

Contact:

Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
susan_berg1@agilent.com
 
Press spacebar to pause and continue. Press esc to stop.